Page 41 - Merck Sharp News Today

DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients ... | April 3, 2023

/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the...

– First treatment option combining an antibody-drug conjugate plus a PD-1 inhibitor in this patient population – ... | April 3, 2023

DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic version of... | June 21, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced the U.S. Food and...

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ... | March 31, 2023

Long-term opioid use increases the risk of abuse and overdose in this population. The study was published as a preprint and has not yet been peer reviewed.

Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.